Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro–Brain Natriuretic Peptide in Patients With Acute Dyspnea
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Amino (N)-terminal pro-brain natriuretic peptide (NT-proBNP) testing is useful for diagnostic and prognostic evaluation in patients with dyspnea. An inverse relationship between body mass index (BMI); (calculated as weight in kilograms divided by height in meters squared) and NT-proBNP concentrations has been described. METHODS: One thousand one hundred three patients presenting to the emergency department with acute dyspnea underwent analysis. Patients were classified into the following 3 BMI categories: lean (<25.0), overweight (25.0-29.9), and obese (>/=30.0). RESULTS: The NT-proBNP concentrations in the overweight and obese groups were significantly lower than in the lean patients, regardless of the presence of acute heart failure (P<.001). The positive likelihood ratio for an NT-proBNP-based diagnosis of acute heart failure was 5.3 for a BMI lower than 25.0, 13.3 for a BMI of 25.0 to 29.9, and 7.5 for a BMI of 30.0 or higher. A cut point of 300 ng/L had very low negative likelihood ratios in all 3 BMI categories (0.02, 0.03, and 0.08, respectively). Among decedents, the NT-proBNP concentrations were lower in the overweight and obese patients compared with the lean subjects (P<.001). Nonetheless, a single cut point of 986 ng/L strongly predicted 1-year mortality across the 3 BMI strata, regardless of the presence of acute heart failure (hazard ratios, 2.22, 3.06, and 3.69 for BMIs of <25.0, 25.0-29.9, and >/=30.0, respectively; all P<.004); the risk associated with a high NT-proBNP concentration was detected early and was sustained to a year after baseline in all 3 BMI strata (all P<.001). CONCLUSIONS: In patients with and without acute heart failure, the NT-proBNP concentrations are relatively lower in overweight and obese patients with acute dyspnea. Despite this, the NT-proBNP concentration retains its diagnostic and prognostic capacity across all BMI categories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impact of Obesity on Plasma Natriuretic Peptide Levels
Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Wilson, P. W. F., & Vasan, R. S. (2004) · Circulation · doi:10.1161/01.cir.0000112582.16683.ea · Cited by 1,022 · cited 2×
“This is unlikely, as several analyses have now shown that this inverse relationship between BMI and natriuretic peptide concentrations is independent of ischemic heart disease and ventricular function.(10,17) Finally, although we previously showed improved diagnostic utility for NT-proBNP concentration by using an age…”
BackgroundThe relationship between obesity and mortality in patients with heart failure
Horwich, T. B., Fonarow, G. C., Hamilton, M. A., MacLellan, W. R., Woo, M. A., & Tillisch, J. H. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01448-6 · Cited by 867
Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure
Kistorp, C., Faber, J., Galatius, S., Gustafsson, F., Frystyk, J., Flyvbjerg, A., & Hildebrandt, P. (2005) · Circulation · doi:10.1161/circulationaha.104.530972 · Cited by 605
Obesity and suppressed B-type natriuretic peptide levels in heart failure
Mehra, M. R., Uber, P. A., Park, M. H., Scott, R. L., Ventura, H. O., Harris, B. C., & Frohlich, E. D. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.066 · Cited by 534 · cited 10×
“Similar trends across BMI strata were observed in those with and without acute HF. Figure 3 illustrates NT-proBNP concentrations as a function of mortality status in the 3 BMI categories.”
ResultInfluentialBody composition and prognosis in chronic systolic heart failure: the obesity paradox
Lavie, C. J., Osman, A. F., Milani, R. V., & Mehra, M. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00031-6 · Cited by 486
Murphy, N. F., MacIntyre, K., Stewart, S., Hart, C. L., Hole, D., & McMurray, J. J. V. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi506 · Cited by 298
Lavie (2003) · doi:10.1016/s0735-1097(03)00784-8 · Cited by 160
Cited by
State of the art: using natriuretic peptide levels in clinical practice
Maisel, A., Mueller, C., Adams, K., Anker, S. D., Aspromonte, N., Cleland, J. G. F., Cohen-Solal, A., Dahlstrom, U., DeMaria, A., Di Somma, S., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.07.014 · Cited by 839
“It is always of greatest value when it complements the physician's clinical skills along with other available diagnostic tools and should always be interpreted in consideration of renal function and body mass index (BMI).”
BackgroundMethodInfluentialMueller, C., McDonald, K., de Boer, R. A., Maisel, A., Cleland, J. G. F., Kozhuharov, N., Coats, A. J. S., Metra, M., Mebazaa, A., Ruschitzka, F., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1494 · Cited by 804
Self-citationBiomarkers and diagnostics in heart failure
Gaggin, H. K., & Januzzi, J. L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.12.014 · Cited by 423
Madamanchi, C., Alhosaini, H., Sumida, A., & Runge, M. S. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.08.007 · Cited by 357
Obesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313
Metadata
- Authors
- Bayes-Genis, A.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2007-02-26
- Volume
- 167
- Issue
- 4
- Pages
- 400
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2011746283
- Cited by
- 151
- References
- 7
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.